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Abstract
Objective: Stevens-Johnson Syndrome (SJS) is one of the most severe muco-cutaneous diseases and its occurrence is often
attributed to drug use. The aim of the present study is to quantify the risk of SJS in association with drug and vaccine use in
children.
Methods: A multicenter surveillance of children hospitalized through the emergency departments for acute conditions of
interest is currently ongoing in Italy. Cases with a diagnosis of SJS were retrieved from all admissions. Parents were
interviewed on child’s use of drugs and vaccines preceding the onset of symptoms that led to the hospitalization. We
compared the use of drugs and vaccines in cases with the corresponding use in a control group of children hospitalized for
acute neurological conditions.
Results: Twenty-nine children with a diagnosis of SJS and 1,362 with neurological disorders were hospitalized between 1st
November 1999 and 31st October 2012. Cases were more frequently exposed to drugs (79% vs 58% in the control group;
adjusted OR 2.4; 95% CI 1.0–6.1). Anticonvulsants presented the highest adjusted OR: 26.8 (95% CI 8.4–86.0). Significantly
elevated risks were also estimated for antibiotics use (adjusted OR 3.3; 95% CI 1.5–7.2), corticosteroids (adjusted OR 4.2; 95%
CI 1.8–9.9) and paracetamol (adjusted OR 3.2; 95% CI 1.5–6.9). No increased risk was estimated for vaccines (adjusted OR:
0.9; 95% CI 0.3–2.8).
Discussion: Our study provides additional evidence on the etiologic role of drugs and vaccines in the occurrence of SJS in
children.
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Introduction
Adverse drug reactions (ADRs) in children are an important
public health problem. Two systematic reviews of observational
studies on ADRs causing paediatric hospitalizations showed an
estimated admission rate of 2.1% (95% CI 1.0%–3.8%) between
1976 and 1996 [1], and of 2.9% (95% CI 2.6%–3.1%) in the
period from 1964 to 2009 [2].
Cutaneous ADRs are the most frequently reported ADRs both
in adults and children [3]. These events are generally mild and
self-limiting, although in rare instances they can be life threatening
[4], [5]. Stevens-Johnson Syndrome (SJS) and Toxic Epidermal
Necrolysis (TEN) are the most serious conditions, characterized by
extensive detachment of epidermis and erosions of mucous
membranes [4], [6]. The two conditions are considered to differ
in their severity, with the extent of skin detachment being ,10%
for SJS, .30% for TEN and between 10 and 30% for so called
SJS-TEN overlap. The estimated incidence is 1–7 cases per
million person-years for SJS and 0.4–1.5 cases per million person-
years for TEN [7].
In adults, between 60% and 70% of SJS and TEN was
attributed to drug use [8], [9]. However, the overall evidence
concerning the relationship between drugs and the occurrence of
SJS and TEN in children is still limited, because of the rarity of the
disease and the scarcity of observational studies. The most relevant
findings derive from a pooled analysis [10] that focused on
children (age ,15 years) enrolled in two large case-control studies
conducted in the general population [11], [12]. Drugs strongly
associated with the occurrence of SJS and TEN were anti-infective
sulphonamides, phenobarbital, carbamazepine and lamotrigine.
An increased risk was also observed for valproic acid, non-steroidal
anti-inflammatory drugs (NSAIDs), and paracetamol [10].
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Since 1999 an active surveillance aimed at ascertaining the role
of drugs and vaccines in the occurrence of specific acute conditions
responsible for the hospitalization of paediatric patients has been
conducted in Italy [13], [14], [15]. Non-infective muco-cutaneous
diseases were among the conditions included in the surveillance
and we focused on cases of SJS and TEN to contribute further
information on the causal role of drugs and vaccines. The aim of
the study was to provide risk estimates of medicines that are
already known to be associated with SJS or TEN and to point out
potential new signals.
Methods
Ethics Statement
The protocol of the study was approved by the Ethical
Committee of the participating clinical centres: Regina Margherita
Children’s Hospital (Torino), Giannina Gaslini Paediatric Hospital
(Genova); Department of Paediatrics, University Hospital (Pa-
dova); Anna Meyer Children’s University Hospital (Firenze);
Department of Paediatrics, University Hospital (Perugia); Phar-
macology and Paediatrics and Developmental Neuroscience,
Universita` Cattolica Sacro Cuore (Roma); Emergency Depart-
ment, Bambino Gesu` Children Hospital (Roma); Santobono-
Pausilipon Paediatric Hospital (Napoli); Giovanni Di Cristina
Paediatric Hospital (Palermo). Written informed consent to use
data for research purposes was obtained before conducting
parents’ interview.
Setting and Study Population
The Italian multicentre surveillance on drug and vaccine safety
in children is an ongoing active observational study coordinated by
the Italian National Institute of Health. The surveillance currently
includes nine paediatric hospitals/wards spread throughout the
country (Genoa, Turin, Padua, Florence, Perugia, Rome (two
hospitals), Naples and Palermo).
The population included in the surveillance consisted of all
children (age $1 month to 18 years) who visited the emergency
department of the participating centers and were hospitalized for
one of the following acute conditions: non-infectious muco-
cutaneous diseases; neurological disorders; gastroduodenal lesions;
thrombocytopenia. General exclusion criteria were represented by
a concomitant diagnosis of cancer or immunodeficiency. Within
the neurological disorders, febrile seizure, non-incident convul-
sions (children with a previous diagnosis of epilepsy), and
headaches were also excluded.
Data Collection
Parents were interviewed by a trained pharmacist/physician
using a structured questionnaire and data on medical history and
exposure to drugs and vaccines were collected. Specifically, drug
use was considered of interest for the 3 weeks preceding the onset
of symptoms (the index date), whereas the time window for vaccine
administration was extended to 6 weeks (12 weeks since October
2009). For all children, the inclusion in the surveillance was based
on the clinical diagnosis and was consequently independent on the
information on previous exposure to drugs and vaccines. Further
details on the study methodology can be found elsewhere [15].
Definition of Cases and Controls
Cases included children hospitalized through the emergency
department for a muco-cutaneous condition who were discharged
with a final diagnosis of SJS or TEN. Diagnosis were validated
reviewing the clinical records and, among the others, the following
information was extracted: site of mucosal lesions (eye, mouth,
anus); dermatological consultation; and pharmacological treat-
ments administered during the hospitalization.
Control subjects were all children hospitalized in the partici-
pating centers for non-convulsive neurological conditions. These
conditions were considered a valid control group, as source
population of SJS or TEN cases, since they represent acute
conditions admitted, as for the cases, through the emergency
departments of the same centres. Children hospitalized for
gastroduodenal lesions and for thrombocytopenia were excluded
from the control group because these conditions are frequently
associated with drug exposure.
Analysis
Demographic characteristics of SJS patients, together with the
exposure to drugs and vaccines preceding the onset of symptoms
(index date), are presented on an individual basis. Cases and
controls were compared with regard to the exposure to drugs and
vaccines before the index date. To take into account the possibility
that some drugs may have been prescribed to treat the preliminary
symptoms of SJS, a further analysis was conducted after excluding
drug use initiated in the index date or in the 2 previous days.
Crude and adjusted Odds Ratios (ORs), with 95% Confidence
Intervals (CI), were estimated through a logistic regression model.
The potential confounding role of age and concomitant use of any
other drug was taken into account in the estimates of the adjusted
ORs. Data were analysed with SPSS (v. 17.0).
Results
Out of 2,483 children hospitalized for a muco-cutaneous
condition between 1st November 1999 and 31st October 2012,
37 (1.5%) were hospitalized with a suspected SJS or TEN. We
were able to retrieve the clinical records of 35 children (95%). The
validation procedure did not confirm 8 cases (22%). The diagnosis
of the not confirmed cases were: staphylococcal erythema (3 cases);
Table 1. Characteristics of the study population.
Cases Controls*
Number 29 1,362
Median age (range) 3 y
(4 m–12 y)
4 y
(1 m–19 y)
% Females 48 50
Anamnestic allergy: N (%) 2 (7) 86 (6)
Median length of hospital stay (days) 9 6
Children exposed to drugs: N (%) 23 (79) 796 (58)
Children exposed to vaccines: N (%) 4 (14) 137 (10)
Neurological conditions
Disturbances of consciousness: N (%) 617 (45)
ALTE: N (%) 160 (12)
Movement disorders: N (%) 133 (10)
Other neurological disorders: N (%) 120 (9)
Peripheral neuropathies: N (%) 110 (8)
Infectious and parainfectious
neuropathies: N (%)
89 (6)
Psychological disorders: N (%) 71 (5)
Vertigo: N (%) 62 (5)
*Neurological conditions.
doi:10.1371/journal.pone.0068231.t001
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erythema multiforme (2 cases); Kawasaki disease (1 case); unspec-
ified cutaneous adverse drug reaction (1 case); and cutaneous rash
(1 case). Twenty-nine children with a diagnosis of SJS or TEN
were analyzed (also including the two children with missing
clinical record). In twenty-five cases either a dermatologist or a
plastic surgeon was consulted during the hospitalization.
In the same period, 1,362 children diagnosed with neurological
disorders were also included in the surveillance. The most frequent
diagnosis in the control group were: disturbances of consciousness
(such as syncope, faintness, dizziness, somnolence), apparent life
threatening events (ALTE), movement disorders (eg. extrapyra-
midal symptoms) (Table 1). Cases and controls presented no
differences in the male to female ratio, whereas cases were younger
than controls, with a median age of 3 and 4 years respectively. A
positive anamnesis of systemic allergic manifestations was reported
in 2 SJS cases (7%) and in 86 children in the control group (6%).
The median duration of hospitalization of SJS cases was 9 days
(25th to 75th percentile 4–11), three days longer than in the control
group.
Only one case of TEN was included, a 48 month old girl
exposed to an epicutaneous patch testing for mercury allergy.
Cases were more frequently exposed to drugs in the three weeks
preceding the onset of symptoms (79% vs 58% in the control
group; OR adjusted by age: 2.4; 95% CI 1.0–6.1). The proportion
of children exposed to vaccines were 14% among cases and 10%
among controls, even though the difference was almost entirely
explained by the difference in the age distribution (adjusted OR
0.9; 95% CI 0.3–2.8).
Only 5 of the 29 cases (17%) did not receive either drugs or
vaccines before the index date. The main characteristics of each
SJS or TEN case are detailed in Table 2.
The duration of drug use was generally short, with the exception
of homeopathic remedies and food supplements. Nine children
(out of the 23 with previous use of drugs) continued to receive,
after admission, at least one of the drugs that were used prior to
the hospitalization. All patients fully recovered from SJS or TEN.
Crude and adjusted ORs (adjustment by age and concomitant
use of any other drugs) were estimated for all drugs with at least 2
exposed cases (Table 3). Antiepileptics presented the highest
adjusted OR: 26.8 (95% CI 8.4–86.0). Within this category, the
adjusted OR for valproic acid was 48.1 (95% CI 9.7–237.5), even
though 1 out of the 3 exposed children recovered despite the
treatment continued during hospitalization. The second largest
risk was estimated for corticosteroids (adjusted OR: 4.2; 95% CI
1.8–9.9), followed by antibiotics (adjusted OR: 3.3; 95% CI 1.5–
7.2), with overlapping confidence intervals of the various antibiotic
categories. Significantly elevated risks were also estimated for
paracetamol (adjusted OR: 3.2; 95% CI 1.5–6.9), but not for
NSAIDs use (adjusted OR: 2.4; 95% CI 0.8–7.3).
Only minor changes were observed in the OR estimates when
the sensitivity analysis was carried out by considering unexposed
both cases and controls with drug use started in the index date or
in the two previous days. Specifically, with regard to any drug use,
21 cases and 623 controls were still exposed (adjusted OR: 2.9;
95% CI 1.2–6.6). Negligible differences were also observed for
drug use more sensitive to the shift in the exposure window:
antibiotics (adjusted OR: 4.2; 95% CI 1.8–9.4); corticosteroids
(adjusted OR: 4.1; 95% CI 1.7–10.1); paracetamol (adjusted OR:
2.9; 95% CI 1.3–6.5). No increased risk was observed for NSAIDs
(adjusted OR: 1.2; 95% CI 0.3–5.5).
An increased risk was estimated for concomitant use of
antibiotics and paracetamol (adjusted OR: 5.1; 95% CI 2.0–
13.2). However, when the time window of exposure did not
include the drugs assumed in the two days before the onset of
symptoms the adjusted OR decreased to 3.9 (95% CI 1.3–11.9),
similar to the risk estimates observed for antibiotics alone.
Table 3. Odds ratio of SJS and TEN associated with drugs use.
Drugs Cases Controls* Crude OR Adjusted OR**
(29) (1,362) (95% CI) (95% CI)
Any Antibiotics 11 177 5.9 (2.1–16.1) 3.3 (1.5–7.2)
Any Penicillins 4 80 4.7 (1.3–17.1) 2.1 (0.7–6.3)
Amoxicillin+clavulanic acid 4 61 6.2 (1.7–22.5) 2.8 (0.9–8.4)
Any Cephalosporins 5 60 7.9 (2.3–26.5) 3.6 (1.3–9.9)
Cephaclor 2 16 11.8 (2.2–63.0) 4.9 (1.1–22.8)
Macrolides 3 36 7.9 (1.9–32.7) 3.2 (0.9–11.2)
Any Antiepileptics 5 13 36.3 (9.8–134.2) 26.8 (8.4–86.0)
Valproic acid 3 5 56.6 (11.0–292.3) 48.1 (9.7–237.5)
Any NSAIDs 4 88 4.3 (1.2–15.5) 2.4 (0.8–7.3)
Ibuprofen 3 44 6.4 (1.6–26.6) 3.3 (0.9–11.5)
Paracetamol 11 202 5.1 (1.9–14.1) 3.2 (1.5–6.9)
Paracetamol and antibiotics 6 56 10.1 (3.2–32.4) 5.1 (2.0–13.2)
Corticosteroids 9 108 7.9 (2.7–22.5) 4.2 (1.8–9.9)
Total drug use 23 796 2.7 (1.1–6.7) 2.4 (1.0–6.1)***
Non users 6 566
*Neurological conditions.
**OR adjusted for age and concomitant use of other drugs.
***OR adjusted for age.
doi:10.1371/journal.pone.0068231.t003
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Discussion
Our study provides additional evidence concerning the etiologic
role of drugs and vaccines in the occurrence of SJS in children. In
particular, an increased risk of twenty-seven times was estimated
for antiepileptic drugs. A three times increased risk was observed
for antibiotics, even though the limited power of the study does not
allow to differentiate between the three main classes: penicillins,
cephalosporins and macrolides. Among the other drugs, a
statistically significant increased risk was observed for paracetamol
and corticosteroids, with OR estimates ranging between 3.2 and
4.2.
Our findings are coherent with those of the pooled analysis of
two international multicenter case-control studies [10] in which 80
children with SJS or TEN and 216 controls were analysed. All the
estimates were generally lower in our study, even though entirely
compatible when considering that the confidence intervals
estimated in the international study were quite large, since either
only one or no controls were exposed in many drug categories. For
instance, the OR estimates associated with corticosteroids use were
5.6 (95% CI 0.8–‘) in the Levi’s study and 4.2 (95% CI 1.8–9.9) in
ours.
The high proportion of cases exposed to at least one drug was
similar to that reported by Levi et al. (79% vs 92%), despite a
different definition of the risk period considered for the evaluation
of exposure: 3 weeks preceding the index date in our study and
7 days in the Levi et al. An interval of 7 days after last exposure
was considered consistent with the pharmacokinetics hypothesis
that a drug could not induce any reaction if totally eliminated from
the body [10]. In our study, with the exception of vaccines, the
great majority of drug use was still occurring in the last week
preceding the index day. The beginning of treatment is also of
interest, and our time window for drug exposure is coherent with
the natural history of SJS. For instance, the ALDEN (ALgorithm
of Drug causality for Epidermal Necrosis) criteria for the causality
assessment of drug-related SJS consider a delay from initial drug
intake to the onset of the event as ‘‘suggestive’’ from 5 to 28 days,
and ‘‘compatible’’ from 29 to 56 days [16].
Only one case of TEN was included in our study, whereas in the
pooled case-control study 27 of the 80 cases (34%) received a
diagnoses of TEN [10]. The discrepancy may be partly explained
by the difference in the children’s age (a median of 3 years in our
study and 6 years in the Levi et al.), since a better prognosis has
been suggested for younger patients [17], [18].
We are aware of the difficulties in the diagnosis of SJS in the
clinical practice, especially in children. However, the nine
hospitals included in the Italian study are among the most
renowned centers: five of them are paediatric hospitals (teaching
and non-teaching hospitals) and the remaining four are teaching
departments. The validation procedure was performed in almost
all cases and only one of the two children whose clinical record
was not retrieved was exposed to drugs. When the 8 cases with not
confirmed diagnosis were included in a sensitivity analysis, no
change was observed in the OR estimates.
A possible misclassification of more severe cases (TEN) should
not bias the OR estimates, since SJS and TEN are considered as
two variants of the same disease, whose occurrence is related to
drug exposure in around 70% of the instances [9]. A reduction of
the study power would be expected if more severe cases were lost
in our surveillance. The possibility that some cases of erythema
multiforme majus were classified as SJS and included as cases even
after the validation process is unlikely. This misclassification would
cause an underestimate of the ORs related to drug use, under the
hypothesis that erythema multiforme were less strongly associated
with drug exposure. However, erythema multiforme is one of the
eligible conditions and the differential diagnosis with SJS is
expected to be performed during the hospitalization. During the
study period, 47 out of the 2,483 children who were hospitalized
for muco-cutaneous conditions (1.8%) received a diagnosis of
erythema multiforme.
It is unlikely that the diagnosis of SJS was influenced by the
information on exposure since the drug anamnesis was ascertained
by an independent monitor. It is also unlikely that the recall bias
may explain the increased risks observed in our study since both
cases and controls were hospitalized for acute conditions in the
same setting. Furthermore, the study was performed without any
predefined hypothesis and thus selection of cases associated with
specific drug exposures can be reasonably excluded.
Despite the fact that only 29 children with SJS were enrolled,
they represented the second largest, and probably the youngest
(median age: 3 years) series of cases included in an observational
study. Even though SJS is an extremely rare disease, given the
severity of the condition it is important to further investigate
possible associations with drugs. This will contribute to a more
precise estimate on the role of drugs already implicated in the
occurrence of SJS and confirm and/or highlight potential new
signals.
In recent years, the discovery of the association between HLA
alleles and some cutaneous ADRs (such as allopurinol-associated
SJS and SJS associated with aromatic amine anticonvulsants)
provided an important progress in knowledge [19]. Performing
HLA and genome-wide analyses in children with severe cutaneous
ADRs was not among the objectives of our study. However,
current surveillance systems, together with new observational
studies in children, may be encouraged to verify the hypothesis of
genetic variation leading to altered metabolism of drugs, especially
for category of drugs as anticonvulsants that are targeted at well
defined groups of patients. The general rule of assessing the
benefit/risk of each treatment and avoiding inappropriate
prescriptions will remain the safest behavior to reduce the
occurrence of SJS related to drugs of more common use.
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